BeOne Medicines (ONC) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BeOne Medicines has completed a phase 1 trial called “A Phase 1, Single-dose, Open-label, Randomized, Crossover Study in Healthy Adult Participants to Evaluate Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332).” The study looks at how well a new combo cancer tablet is absorbed and how food changes its levels in the body, which matters for later dosing and approvals.
The trial tests BG-71332, a single fixed-dose pill that combines zanubrutinib and sonrotoclax. The goal is to see if this combo pill works in the body as well as taking zanubrutinib and sonrotoclax separately, and to learn how best to take it with or without food.
This is an interventional phase 1 study in healthy adults with a randomized crossover design. Everyone receives each treatment in turn, there is no placebo, no blinding, and the main aim is to compare drug exposure and food effect rather than to test cancer outcomes.
The study was first submitted on 2025-08-19, marking the start of public tracking of the trial. The most recent update on 2026-03-23 shows the status as completed, which means dosing and primary data collection are done and the program can move toward full analysis and planning of later-stage trials.
For investors, the update supports BeOne’s effort to simplify dosing and improve patient convenience with a combo BTK/BCL-2 pill, similar in concept to other targeted oncology pairings in development. While phase 1 bioavailability data do not move revenue near term, a clean readout could strengthen confidence in BeOne’s pipeline versus larger oncology players and support sentiment for ONC ahead of future efficacy trials.
The study is now completed and recently updated, with further details available on the ClinicalTrials portal.
To learn more about ONC’s potential, visit the BeOne Medicines drug pipeline page.